Your Top Three Stocks For This Christmas!
Integrated biosci research, consultant
Seeking Alpha Analyst Since 2013
As an astute devotee of Warren Buffet, Ben Graham, Phillip Fisher, Sir John Templeton, and Peter Lynch, Dr. Harvey devoured any resources/books on these gurus to learn their craft for over two decades. In the process, he refined their investment approaches specifically to biotech and founded Integrated BioSci Investing: The Number #1 Biotech Service for Long-Term Growth Investing and Power Catalyst Trading.
Since inception, our flagship portfolio has delivered over 31.23% annual average (i.e. 187.39% for roughly six years). As you can appreciate, we’re adept at assisting and serving institutional/retail investors/traders who are looking for alpha. Dividend investors wanting to boost your return can also benefit greatly from our investment research. We currently have over 20 docs in our service for us to tap into their clinical insight for your gains.
Check out some of our binary event forecasts that lead to meteoric gain like the 359% single-day pop from Madrigal Pharmaceuticals (MDGL)’s NASH data release. During his training at the world-renown Columbia University, Harvey Tran, M.D., M.S., developed a passion/edge for analyzing the intricacies of various preclinical/clinical studies, biostatistics, and science/medicine. Importantly, it allowed the physician-scientist Harvey to realize the internal working of various therapeutic in-development that the market tends to overlook.
In recent years, Dr. Harvey founded and led two healthcare roll-up companies. The endeavor helped him gain deep insight into the inner working of a corporate board. His experience as a consultant to common/professional investors and institutions gave him a huge advantage in biotech analysis. The combination of elite training and a passion for biotech provided Dr. Harvey with an aptitude for delivering highly accurate clinical data forecasting that is crucial to picking winning biotech investments for you.
Follow us for the latest research. And, take our FREE 2-week trial to Integrated BioSci Investing to start your winning process now!
Check out Dr. Harvey’s LinkTree for his complete experience. You can make your one good decision a year as Mr. Buffett recommended by checking out Integrated BioSci Investing!
As you're gearing up for New Year 2021, I want to give you another gift.
That is to say, I carefully vetted three stellar stocks for you to buy for 2021.
For most IBI stocks, don't worry if they tumbled.
That's because they have a very good chance of rebounding to a new high.
You recently saw that with Crispr Therapeutics (CRSP).
There's also Alpine Immune Sciences (ALPN), and etc.
Remember that article where Robyn Conti featured me?
It's called Biotech: The Big Payoff.
At the end of that interview, the stellar former SA marketing director asked me to share my number one stock recommendation.
I said, ALPN.
As you know, ALPN disappointed investors for most of 2018.
Nevertheless, I didn't give up on ALPN.
As such, I recommended it again in 2018.
Again, ALPN disappointed all of us.
It made me look bad but I did not give up on it.
What helped me stick to my intuition is Peter Lynch's wisdom.
He said that, just because a stock goes down, doesn't mean you're wrong, and vice versa.
It's the long-term results that mattered most.
As such, I believe in the therapeutics merits of its medicines (ALPN-101 and 202).
Even when it's a very young company, I still believe in it.
After all, I forecasted its clinical outcomes years out in advance.
As it turned out, ALPN continued to post strong early data.
As a result, Abbvie (ABBV) formed a partnership with ALPN earlier this year.
Hence, the stock is catapulted over 80% in one day.
Now even in the thick of COVID, ALPN continues to climb to $15.90.
Like Mirati Therapeutics (MRTX), another 13.9 fold winner for IBI, I believe there are substantially more upsides to ALPN.
All that being said, here are your three stocks with much upsides for 2021:
1) ALPN
2) MRTX
3) CryoPort (CYRX)
Don't miss out on the new research I wrote on MRTX.
And, you don't want to miss out on my comprehensive TOP Picks for New Year 2021. I'll feature it exclusively inside IBI next week!
At IBI: Everyone is getting smarter. Everyone is respected. You don't feel like a fool. And you’re a part of something bigger than yourself.
Inside IBI, we stay ahead of the market!
I'm so confident in the value of my service that I'm giving you a 2-week FREE trial, money-back guarantee.
GET YOUR FREE GIFT TO PROFITABILITY NOW!
Analyst's Disclosure: I am/we are long ALPN.
As a medical doctor/market expert, I'm not a registered investment advisor. Despite that I strive to provide the most accurate information, I neither guarantee the accuracy nor timeliness. Past performance does NOT guarantee future results. I reserve the right to make any investment decision for myself and my affiliates pertaining to any security without notification except where it is required by law. I'm also NOT responsible for the action of my affiliates. The thesis that I presented may change anytime due to the changing nature of information itself. Investing in stocks and options can result in a loss of capital. The information presented should NOT be construed as recommendations to buy or sell any form of security. My articles are best utilized as educational and informational materials to assist investors in your own due diligence process. That said, you are expected to perform your own due diligence and take responsibility for your action. You should also consult with your own financial advisor for specific guidance, as financial circumstances are individualized.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.